S&P 500   3,901.82
DOW   31,535.51
QQQ   323.59
S&P 500   3,901.82
DOW   31,535.51
QQQ   323.59
S&P 500   3,901.82
DOW   31,535.51
QQQ   323.59
S&P 500   3,901.82
DOW   31,535.51
QQQ   323.59
Log in
NASDAQ:CLLS

Cellectis Competitors

$22.69
+1.19 (+5.53 %)
(As of 03/1/2021 12:00 AM ET)
Add
Compare
Today's Range
$21.81
Now: $22.69
$23.17
50-Day Range
$20.64
MA: $27.32
$33.25
52-Week Range
$7.32
Now: $22.69
$34.71
Volume226,627 shs
Average Volume449,110 shs
Market Capitalization$964.01 million
P/E RatioN/A
Dividend YieldN/A
Beta2.59

Competitors

Cellectis (NASDAQ:CLLS) Vs. NK, RLAY, NSTG, RVMD, EDIT, and SRNE

Should you be buying CLLS stock or one of its competitors? Companies in the industry of "biological products, except diagnostic" are considered alternatives and competitors to Cellectis, including NantKwest (NK), Relay Therapeutics (RLAY), NanoString Technologies (NSTG), Revolution Medicines (RVMD), Editas Medicine (EDIT), and Sorrento Therapeutics (SRNE).

Cellectis (NASDAQ:CLLS) and NantKwest (NASDAQ:NK) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, dividends, profitability, valuation, risk and analyst recommendations.

Risk and Volatility

Cellectis has a beta of 2.59, meaning that its stock price is 159% more volatile than the S&P 500. Comparatively, NantKwest has a beta of 2.61, meaning that its stock price is 161% more volatile than the S&P 500.

Valuation and Earnings

This table compares Cellectis and NantKwest's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cellectis$22.99 million41.93$-102,090,000.00($2.41)-9.41
NantKwest$40,000.0090,740.00$-65,790,000.00($0.70)-47.57

NantKwest has lower revenue, but higher earnings than Cellectis. NantKwest is trading at a lower price-to-earnings ratio than Cellectis, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

33.3% of Cellectis shares are held by institutional investors. Comparatively, 9.4% of NantKwest shares are held by institutional investors. 16.4% of Cellectis shares are held by insiders. Comparatively, 71.7% of NantKwest shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares Cellectis and NantKwest's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Cellectis-110.52%-23.56%-16.69%
NantKwest-76,658.58%-56.06%-46.93%

Analyst Ratings

This is a summary of recent ratings and price targets for Cellectis and NantKwest, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Cellectis11302.40
NantKwest00103.00

Cellectis currently has a consensus target price of $24.25, indicating a potential upside of 6.88%. NantKwest has a consensus target price of $18.00, indicating a potential downside of 45.95%. Given Cellectis' higher probable upside, equities research analysts clearly believe Cellectis is more favorable than NantKwest.

Summary

Cellectis beats NantKwest on 8 of the 14 factors compared between the two stocks.

Relay Therapeutics (NASDAQ:RLAY) and Cellectis (NASDAQ:CLLS) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, dividends, profitability, valuation, earnings, institutional ownership and risk.

Earnings and Valuation

This table compares Relay Therapeutics and Cellectis' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Relay TherapeuticsN/AN/AN/AN/AN/A
Cellectis$22.99 million41.93$-102,090,000.00($2.41)-9.41

Relay Therapeutics has higher earnings, but lower revenue than Cellectis.

Institutional and Insider Ownership

98.4% of Relay Therapeutics shares are held by institutional investors. Comparatively, 33.3% of Cellectis shares are held by institutional investors. 16.4% of Cellectis shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Profitability

This table compares Relay Therapeutics and Cellectis' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Relay TherapeuticsN/AN/AN/A
Cellectis-110.52%-23.56%-16.69%

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Relay Therapeutics and Cellectis, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Relay Therapeutics01502.83
Cellectis11302.40

Relay Therapeutics currently has a consensus price target of $57.40, indicating a potential upside of 42.82%. Cellectis has a consensus price target of $24.25, indicating a potential upside of 6.88%. Given Relay Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Relay Therapeutics is more favorable than Cellectis.

Summary

Relay Therapeutics beats Cellectis on 7 of the 9 factors compared between the two stocks.

NanoString Technologies (NASDAQ:NSTG) and Cellectis (NASDAQ:CLLS) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, dividends, profitability, valuation, earnings, institutional ownership and risk.

Risk & Volatility

NanoString Technologies has a beta of 1.77, indicating that its stock price is 77% more volatile than the S&P 500. Comparatively, Cellectis has a beta of 2.59, indicating that its stock price is 159% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for NanoString Technologies and Cellectis, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
NanoString Technologies01402.80
Cellectis11302.40

NanoString Technologies currently has a consensus price target of $55.8333, indicating a potential downside of 24.91%. Cellectis has a consensus price target of $24.25, indicating a potential upside of 6.88%. Given Cellectis' higher probable upside, analysts plainly believe Cellectis is more favorable than NanoString Technologies.

Earnings and Valuation

This table compares NanoString Technologies and Cellectis' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NanoString Technologies$125.57 million26.09$-40,700,000.00($1.93)-38.53
Cellectis$22.99 million41.93$-102,090,000.00($2.41)-9.41

NanoString Technologies has higher revenue and earnings than Cellectis. NanoString Technologies is trading at a lower price-to-earnings ratio than Cellectis, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares NanoString Technologies and Cellectis' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
NanoString Technologies-53.47%-68.96%-24.15%
Cellectis-110.52%-23.56%-16.69%

Institutional and Insider Ownership

98.3% of NanoString Technologies shares are held by institutional investors. Comparatively, 33.3% of Cellectis shares are held by institutional investors. 4.2% of NanoString Technologies shares are held by company insiders. Comparatively, 16.4% of Cellectis shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Cellectis (NASDAQ:CLLS) and Revolution Medicines (NASDAQ:RVMD) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, analyst recommendations, profitability, dividends, earnings, risk and institutional ownership.

Analyst Recommendations

This is a breakdown of current ratings for Cellectis and Revolution Medicines, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Cellectis11302.40
Revolution Medicines01402.80

Cellectis presently has a consensus price target of $24.25, indicating a potential upside of 6.88%. Revolution Medicines has a consensus price target of $46.75, indicating a potential upside of 1.65%. Given Cellectis' higher probable upside, equities research analysts plainly believe Cellectis is more favorable than Revolution Medicines.

Valuation and Earnings

This table compares Cellectis and Revolution Medicines' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cellectis$22.99 million41.93$-102,090,000.00($2.41)-9.41
Revolution Medicines$50.04 million61.01$-47,660,000.00N/AN/A

Revolution Medicines has higher revenue and earnings than Cellectis.

Profitability

This table compares Cellectis and Revolution Medicines' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Cellectis-110.52%-23.56%-16.69%
Revolution Medicines-191.17%-32.25%-20.55%

Institutional & Insider Ownership

33.3% of Cellectis shares are owned by institutional investors. Comparatively, 85.8% of Revolution Medicines shares are owned by institutional investors. 16.4% of Cellectis shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Revolution Medicines beats Cellectis on 6 of the 11 factors compared between the two stocks.

Cellectis (NASDAQ:CLLS) and Editas Medicine (NASDAQ:EDIT) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, analyst recommendations, profitability, dividends, earnings, risk and institutional ownership.

Volatility & Risk

Cellectis has a beta of 2.59, indicating that its share price is 159% more volatile than the S&P 500. Comparatively, Editas Medicine has a beta of 2.1, indicating that its share price is 110% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings for Cellectis and Editas Medicine, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Cellectis11302.40
Editas Medicine34302.00

Cellectis presently has a consensus price target of $24.25, indicating a potential upside of 6.88%. Editas Medicine has a consensus price target of $49.7778, indicating a potential upside of 6.16%. Given Cellectis' stronger consensus rating and higher probable upside, equities research analysts plainly believe Cellectis is more favorable than Editas Medicine.

Valuation and Earnings

This table compares Cellectis and Editas Medicine's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cellectis$22.99 million41.93$-102,090,000.00($2.41)-9.41
Editas Medicine$20.53 million143.18$-133,750,000.00($2.68)-17.50

Cellectis has higher revenue and earnings than Editas Medicine. Editas Medicine is trading at a lower price-to-earnings ratio than Cellectis, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Cellectis and Editas Medicine's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Cellectis-110.52%-23.56%-16.69%
Editas Medicine-99.62%-26.74%-16.38%

Institutional & Insider Ownership

33.3% of Cellectis shares are owned by institutional investors. Comparatively, 87.5% of Editas Medicine shares are owned by institutional investors. 16.4% of Cellectis shares are owned by insiders. Comparatively, 0.9% of Editas Medicine shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Cellectis beats Editas Medicine on 9 of the 13 factors compared between the two stocks.

Cellectis (NASDAQ:CLLS) and Sorrento Therapeutics (NASDAQ:SRNE) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, analyst recommendations, profitability, dividends, earnings, risk and institutional ownership.

Volatility & Risk

Cellectis has a beta of 2.59, indicating that its share price is 159% more volatile than the S&P 500. Comparatively, Sorrento Therapeutics has a beta of 2.7, indicating that its share price is 170% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings for Cellectis and Sorrento Therapeutics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Cellectis11302.40
Sorrento Therapeutics00403.00

Cellectis presently has a consensus price target of $24.25, indicating a potential upside of 6.88%. Sorrento Therapeutics has a consensus price target of $28.75, indicating a potential upside of 180.49%. Given Sorrento Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Sorrento Therapeutics is more favorable than Cellectis.

Valuation and Earnings

This table compares Cellectis and Sorrento Therapeutics' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cellectis$22.99 million41.93$-102,090,000.00($2.41)-9.41
Sorrento Therapeutics$31.43 million91.42$-292,070,000.00($2.12)-4.83

Cellectis has higher earnings, but lower revenue than Sorrento Therapeutics. Cellectis is trading at a lower price-to-earnings ratio than Sorrento Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Cellectis and Sorrento Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Cellectis-110.52%-23.56%-16.69%
Sorrento Therapeutics-698.01%-314.06%-43.60%

Institutional & Insider Ownership

33.3% of Cellectis shares are owned by institutional investors. Comparatively, 27.4% of Sorrento Therapeutics shares are owned by institutional investors. 16.4% of Cellectis shares are owned by insiders. Comparatively, 3.4% of Sorrento Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Sorrento Therapeutics beats Cellectis on 8 of the 14 factors compared between the two stocks.

pixel
Ad TCAN MGMT
The Next Emerging Green Powerhouse in California
California is the biggest legal MJ market and one company is about to open a facility in the state that is expected to see $50M the first year. This may be the next MJ stock to shine green!

Cellectis Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
NantKwest logo
NK
NantKwest
1.1$33.30+2.4%$3.63 billion$40,000.00-46.90Decrease in Short Interest
Gap Down
RLAY
Relay Therapeutics
1.8$40.19+2.7%$3.62 billionN/A0.00News Coverage
Gap Down
NanoString Technologies logo
NSTG
NanoString Technologies
1.3$74.36+6.1%$3.28 billion$125.57 million-43.49Earnings Announcement
News Coverage
Gap Down
Revolution Medicines logo
RVMD
Revolution Medicines
1.3$45.99+0.7%$3.05 billion$50.04 million0.00Upcoming Earnings
Editas Medicine logo
EDIT
Editas Medicine
1.2$46.89+6.5%$2.94 billion$20.53 million-26.95Earnings Announcement
Analyst Report
Analyst Revision
Sorrento Therapeutics logo
SRNE
Sorrento Therapeutics
1.3$10.25+5.7%$2.87 billion$31.43 million-7.02Gap Down
AlloVir logo
ALVR
AlloVir
1.4$38.38+4.7%$2.50 billionN/A0.00Gap Down
Vericel logo
VCEL
Vericel
1.3$48.17+0.2%$2.21 billion$117.85 million-4,817,000.00Earnings Announcement
Analyst Downgrade
Analyst Revision
Gap Down
Kymera Therapeutics logo
KYMR
Kymera Therapeutics
0.8$48.46+1.0%$2.15 billionN/A0.00Upcoming Earnings
High Trading Volume
BioCryst Pharmaceuticals logo
BCRX
BioCryst Pharmaceuticals
1.1$11.98+10.0%$2.12 billion$48.83 million-15.76Earnings Announcement
Analyst Report
Analyst Revision
Gap Down
bluebird bio logo
BLUE
bluebird bio
1.8$30.08+3.4%$2.00 billion$44.67 million-2.74
Scholar Rock logo
SRRK
Scholar Rock
1.1$56.80+4.8%$1.91 billion$20.49 million-23.57Gap Down
Ocugen logo
OCGN
Ocugen
1.1$10.02+9.3%$1.88 billionN/A-6.77Decrease in Short Interest
Gap Up
C4 Therapeutics logo
CCCC
C4 Therapeutics
1.1$42.39+1.3%$1.82 billionN/A0.00Upcoming Earnings
Translate Bio logo
TBIO
Translate Bio
1.4$23.80+1.9%$1.77 billion$7.80 million-22.24Analyst Report
Gap Down
Sangamo Therapeutics logo
SGMO
Sangamo Therapeutics
1.3$11.99+4.2%$1.72 billion$102.43 million-19.98Earnings Announcement
Analyst Downgrade
Analyst Revision
News Coverage
Gap Down
Krystal Biotech logo
KRYS
Krystal Biotech
1.3$85.46+7.7%$1.68 billionN/A-57.74Earnings Announcement
Upcoming Earnings
Analyst Report
News Coverage
Gap Down
Replimune Group logo
REPL
Replimune Group
1.5$35.42+2.2%$1.65 billionN/A-20.01Gap Down
REGENXBIO logo
RGNX
REGENXBIO
1.8$42.51+3.8%$1.59 billion$35.23 million-17.14Earnings Announcement
News Coverage
Gap Down
FMTX
Forma Therapeutics
1.8$38.49+0.3%$1.58 billion$100.56 million0.00Upcoming Earnings
Decrease in Short Interest
Immunovant logo
IMVT
Immunovant
1.8$14.85+6.3%$1.45 billionN/A-11.51High Trading Volume
Increase in Short Interest
Gap Down
Alector logo
ALEC
Alector
1.3$17.43+4.3%$1.38 billion$21.22 million-7.82Earnings Announcement
Atara Biotherapeutics logo
ATRA
Atara Biotherapeutics
1.4$17.11+1.9%$1.33 billionN/A-3.70Earnings Announcement
News Coverage
Gap Down
PCVX
Vaxcyte
1.8$25.83+8.8%$1.32 billionN/A0.00Upcoming Earnings
Adverum Biotechnologies logo
ADVM
Adverum Biotechnologies
1.7$13.32+3.7%$1.30 billion$250,000.00-10.49Earnings Announcement
Coherus BioSciences logo
CHRS
Coherus BioSciences
1.4$16.02+1.4%$1.15 billion$356.07 million7.85Earnings Announcement
Gap Down
Mesoblast logo
MESO
Mesoblast
1.4$9.60+0.0%$1.13 billion$32.16 million-10.91Upcoming Earnings
Aligos Therapeutics logo
ALGS
Aligos Therapeutics
1.1$29.20+1.6%$1.11 billionN/A0.00
Inhibrx logo
INBX
Inhibrx
1.5$28.89+12.0%$1.09 billionN/A0.00Upcoming Earnings
Cortexyme logo
CRTX
Cortexyme
1.3$36.43+6.5%$1.07 billionN/A-15.18
Taysha Gene Therapies logo
TSHA
Taysha Gene Therapies
1.8$26.87+4.8%$1.01 billionN/A0.00Upcoming Earnings
Analyst Report
News Coverage
Black Diamond Therapeutics logo
BDTX
Black Diamond Therapeutics
1.6$27.93+0.3%$1.01 billionN/A-4.62Gap Down
TCR2 Therapeutics logo
TCRR
TCR2 Therapeutics
1.5$28.43+6.9%$950.19 millionN/A-11.75Gap Down
Aerie Pharmaceuticals logo
AERI
Aerie Pharmaceuticals
1.7$19.18+4.1%$897.91 million$69.89 million-4.58Earnings Announcement
Analyst Report
News Coverage
Gap Down
Passage Bio logo
PASG
Passage Bio
1.9$19.52+7.7%$896.30 millionN/A0.00Upcoming Earnings
News Coverage
Sutro Biopharma logo
STRO
Sutro Biopharma
1.1$23.00+3.5%$887.89 million$42.74 million-255.56Gap Down
Adaptimmune Therapeutics logo
ADAP
Adaptimmune Therapeutics
1.6$5.73+3.3%$886.88 million$1.12 million-5.79Earnings Announcement
Gap Down
Vaxart logo
VXRT
Vaxart
1.3$7.55+5.3%$826.49 million$9.86 million-12.80Earnings Announcement
Gap Down
Rubius Therapeutics logo
RUBY
Rubius Therapeutics
1.7$9.88+5.1%$802.08 millionN/A-4.62Earnings Announcement
Analyst Downgrade
Agenus logo
AGEN
Agenus
1.6$3.96+1.0%$752.99 million$150.05 million-3.63
Tarsus Pharmaceuticals logo
TARS
Tarsus Pharmaceuticals
1.2$36.79+1.5%$747.57 millionN/A0.00Increase in Short Interest
Gap Down
Orchard Therapeutics logo
ORTX
Orchard Therapeutics
1.6$7.40+5.8%$719.75 million$2.51 million-4.48Analyst Report
Increase in Short Interest
Poseida Therapeutics logo
PSTX
Poseida Therapeutics
1.9$11.29+2.2%$697.95 millionN/A-1.65Upcoming Earnings
Analyst Revision
News Coverage
Gap Down
Athira Pharma logo
ATHA
Athira Pharma
2.2$21.40+3.1%$695.18 millionN/A0.00Upcoming Earnings
Decrease in Short Interest
Compugen logo
CGEN
Compugen
1.4$9.97+6.4%$682.15 million$17.80 million-26.95Earnings Announcement
Analyst Revision
Gap Down
Precision BioSciences logo
DTIL
Precision BioSciences
1.5$12.87+7.1%$675.42 million$22.24 million-6.40Upcoming Earnings
Gap Down
Curis logo
CRIS
Curis
1.1$10.43+5.7%$613.46 million$10 million-12.72Increase in Short Interest
Gap Down
DBV Technologies logo
DBVT
DBV Technologies
1.2$5.46+2.0%$599.83 million$14.75 million-2.34Upcoming Earnings
News Coverage
MeiraGTx logo
MGTX
MeiraGTx
1.4$15.30+3.0%$587.70 million$13.29 million-10.85
Gritstone Oncology logo
GRTS
Gritstone Oncology
1.6$14.08+3.6%$531.72 million$4.36 million-4.92Increase in Short Interest
This page was last updated on 3/2/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.